The use of aprotinin in children undergoing operative repair of isolated atrial septal defects

Paediatric Anaesthesia

Volumn 18, Issue 2, 2008, Pages 145-150

  Chiravuri, S Devi ^a,b   Voepel Lewis, Terri ^a   Devaney, Eric J ^a   Malviya, Shobha ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Aprotinin; Atrial septal defect; Cardiopulmonary bypass; Children; Transfusion

Indexed keywords

APROTININ;

ARTICLE; BLOOD TRANSFUSION; CARDIOPULMONARY BYPASS; CHILD; DRUG COST; FEMALE; HEART ATRIUM SEPTUM DEFECT; HEMATOCRIT; HUMAN; LENGTH OF STAY; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PEDIATRIC ANESTHESIA; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; ULTRAFILTRATION;

APROTININ; BLOOD LOSS, SURGICAL; CARDIOPULMONARY BYPASS; CHILD; CHILD, PRESCHOOL; FEMALE; HEART SEPTAL DEFECTS, ATRIAL; HEMOSTATICS; HUMANS; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; RETROSPECTIVE STUDIES;

EID: 37748999178     PISSN: 11555645     EISSN: 14609592     Source Type: Journal    
DOI: 10.1111/j.1460-9592.2007.02361.x     Document Type: Article

References (15)

1. Arnold DM, Fergusson DA, Chan AK et al. Avoiding transfusions in children undergoing cardiac surgery: a meta-analysis of randomized trials of aprotinin. Anesth Analg 2006 102 : 731 737.
2. Henry DA, Moxey AJ, Carless PA et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 3, 2007.
3. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004 128 : 442 448.
4. Mangano DT, Tudor IC, Dietzel C et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006 354 : 353 365.
5. Karkouti K, Beattie WS, Dattilo KM et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006 46 : 327 338.
6. Mangano DT, Miao Y, Vuylsteke A et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007 297 : 471 479.
7. Boldt J, Knothe C, Zickmann B et al. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss (see comment). J Thorac Cardiovasc Surgery 1993 105 : 705 711.
8. D'Errico CC, Shayevitz JR, Martindale SJ et al. The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesth Analg 1996 83 : 1193 1199.
9. Herynkopf F, Lucchese F, Pereira E et al. Aprotinin in children undergoing correction of congenital heart defects. A double-blind pilot study. J Thorac Cardiovasc Surg 1994 108 : 517 521.
10. Mossinger H, Dietrich W, Braun SL et al. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg 2003 75 : 430 437.
11. Kern FH, Morana NJ, Sears JJ et al. Coagulation defects in neonates during cardiopulmonary bypass. Ann Thorac Surg 1992 54 : 541 546.
12. Naik SK, Knight A, Elliott MJ. A successful modification of ultrafiltration for cardiopulmonary bypass in children. Perfusion 1991 6 : 41 650.
13. Levy JH. Hemostatic agents and their safety. J Cardiothorac Vasc Anesth 1999 13 : 6 11.
14. Dietrich W. Incidence of hypersensitivity reactions. Ann Thorac Surg 1998 65 : S60 S64.
15. Cohen DM, Norberto J, Cartabuke R et al. Severe anaphylactic reaction after primary exposure to aprotinin. Ann Thorac Surg 1999 67 : 837 838.